Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to …
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to … Continue reading "Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports"
The May issue of the Journal of Drugs in Dermatology (JDD) focuses on skin cancer and includes the perfect blend of original articles and case reports. Topics include actinic keratosis versus squamous cell carcinoma, the utility of gene expression profiling in skin cancer, the prevalence of sunscreen use, and many more. Check out this month’s issue highlights straight from the JDD Editor’s … 
INTRODUCTION
Linear lichen planus pigmentosus (LPP) of the face is a rare acquired variant of lichen planus, with only a few cases published in the literature.1 It is an inflammatory condition with unknown etiology, characterized by blue-gray hyperpigmented macules, and tends to affect sun-exposed areas of the head and neck.1-4 The pathophysiology of linear LPP is poorly understood, though … 
INTRODUCTION
Graham-Little-Piccardi-Lasseur Syndrome (GLPLS) is a rare clinical subtype of lichen planopilaris (LPP) that manifests as a triad of scarring alopecia of the scalp, nonscarring alopecia of the axillary and the pubic skin, and widespread lichenoid follicular papules.1 GLPLS more commonly affects women (male-to-female ratio ≃ 1:4), with the classic patient being a middle-aged Ca … 
The April issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, features, and case reports, with topics ranging from hormonal therapy in hidradenitis suppurativa, private equity in dermatology, vitiligo and its associated comorbidities, novel topical products for facial dyschromia, and many more. Check out this month’s issue highlights straight … 